Jinnan Yue
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, HER2/EGFR in Cancer Research, Cytokine Signaling Pathways and Interactions, Cancer-related molecular mechanisms research, RNA modifications and cancer
Most-Cited Works
- → Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin β3(2018)111 cited
- → Acquired Resistance to EGFR TKIs Mediated by TGFβ1/Integrin β3 Signaling in EGFR-Mutant Lung Cancer(2019)67 cited
- → SIRT3-mediated deacetylation of NLRC4 promotes inflammasome activation(2021)67 cited
- → Ubc13 Promotes K63-Linked Polyubiquitination of NLRP3 to Activate Inflammasome(2021)35 cited
- → Acquisition of EGFR TKI resistance and EMT phenotype is linked with activation of IGF1R/NF-κB pathway in EGFR-mutant NSCLC(2017)34 cited
- → Inactivation of M2 AChR/NF-κB signaling axis reverses epithelial-mesenchymal transition (EMT) and suppresses migration and invasion in non-small cell lung cancer (NSCLC)(2015)32 cited
- → Data from Acquired Resistance to EGFR TKIs Mediated by TGFβ1/Integrin β3 Signaling in EGFR-Mutant Lung Cancer(2023)
- → Supplementary Legends and Figure S1-S8 from Acquired Resistance to EGFR TKIs Mediated by TGFβ1/Integrin β3 Signaling in EGFR-Mutant Lung Cancer(2023)
- → [DICER1 and relevant tumor].(2021)
- → [NTRK fusion gene expression in solid tumors and research progress of Trk small molecule inhibitors].(2020)